Standalone and Consolidated Results Q4FY26
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ipca Laboratories reported FY2026 standalone revenue of ₹7,336.75 crore, up 9.9% from ₹6,677.92 crore in FY2025. Standalone PAT jumped 74% to ₹1,132.52 crore from ₹650.76 crore, driven by higher margins and operational efficiency. Consolidated revenue grew 7.9% to ₹9,646.33 crore, with consolidated PAT rising 54.7% to ₹1,141.12 crore. The company declared an unmodified audit opinion, recommended dividend of ₹6 per share (600%), and approved re-appointment of Executive Director Mr. Prashant Godha for 5 years. Key exceptional items included ₹45.82 crore labour code impact and impairments of ₹281.54 crore in the standalone results.
Strong profitability growth with PAT up over 50% indicates operational efficiency gains. The clean audit opinion and dividend declaration are positive signals for investors. However, revenue growth remains modest at under 10%, suggesting the profit surge is driven more by cost management than top-line expansion.